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The objective of the present study is to develop a colon targeted drug delivery systems for Aceclofenac 
using xanthan gum as a carrier. In this study, multilayer coated system that is resistant to gastric and 
small intestinal conditions but can be easily degraded by colonic bacterial enzymes was designed to 
achieve effective colon delivery of Aceclofenac. The xanthan gum, the drug and the physical mixture were 
characterized by Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry 
(DSC). All the formulations were evaluated for hardness, drug content uniformity and other physical 
properties. Release aspects of Aceclofenac in simulated gastrointestinal fluid and colonic fluid with 
enzymes were investigated. From these results, Eudragit coated system exhibited gastric and small 
intestinal resistance to the release of Aceclofenac. The rapid increase in release of Aceclofenac in SCF 
was revealed as due to the degradation of the xanthan gum membrane by bacterial enzymes. The designed 
system could be used potentially as a carrier for colon delivery of Aceclofenac by regulating drug release 
in stomach and the small intestine.
Uniterms: Drugs/release colon targeted. Aceclofenac/release colon targeted. Xanthan gum. Colon 
targeting. Eudragit coating. In vitro dissolution. Targeted delivery. 
O presente estudo teve como objetivo o desenvolvimento de sistema de liberação cólon-alvo de 
aceclofenaco empregando goma xantana. Nesse trabalho, o revestimento de múltiplas camadas com 
característica de resistência às condições do intestino delgado além de gastrorresistência oferece 
como vantagem a rápida degradação desse sistema por enzimas bacterianas colônicas. Dessa forma, o 
planejamento de tal sistema possibilitou a liberação específica do aceclofenaco no cólon. A goma xantana 
e o fármaco, além da mistura física desses dois componentes, foram caracterizados por espectroscopia 
no infravermelho com transformada de Fourier (FTIR) e calorimetria diferencial exploratória (DSC). 
Todas as formulações foram avaliadas no que se refere à dureza, à uniformidade de conteúdo do fármaco 
além de outras propriedades físicas. Os perfis de liberação do aceclofenaco no fluido gástrico simulado e 
fluido colônico simulado contendo enzimas foram investigados. Os resultados revelaram que o sistema 
revestido com Eudragit® exibiu resistência gástrica e intestinal à liberação de aceclofenaco. O rápido 
aumento na liberação de aceclofenaco no fluido colônico simulado foi atribuido à degradação da goma 
xantana por enzimas bacterianas. O sistema apresenta aplicação potencial no desenvolvimento de produtos 
para a liberação cólon-alvo de aceclofenaco. 
Unitermos: Fármacos/liberação cólon-alvo Aceclofenaco/perfil de liberação. Goma xantana. 
Direcionamento ao cólon. Cobertura de Eudragit. Dissolução in vitro. Liberação dirigida.
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INTRODUCTION
The oral route is considered to be most convenient 
for administration of drugs to patients. Oral administration 
of conventional dosage forms normally dissolves in the 
stomach fluid or intestinal fluid and absorb from these 
regions of the gastrointestinal tract (GIT) (Paharia et al., 
2007). Dosage forms that deliver drugs into the colon ra-
ther than upper GIT offers number of advantages (Sarasija, 
Hota, 2000; Vaidya et al, 2009).
Many attempts have been made to achieve colon 
targeting that is advantageous in the treatment of colonic 
disease and as well as in the treatment of rheumatoid ar-
thritis. A novel oral colon-specific drug delivery system 
(CDDS) has been developed as one of the site-specific 
drug delivery systems (Dhawale et al., 2010). This de-
livery system, by means of combination of one or more 
controlled release mechanisms, hardly releases drug in the 
upper part of the gastrointestinal (GIT) tract, but rapidly 
releases drug in the colon following oral administration. 
CDDS is convenient for treating localized colonic disea-
ses, i.e. ulcerative colitis, Crohn’s disease and constipation 
etc., CDDS, also selectively deliver drug to the colon, but 
not to the upper GI tract (Kinget et al., 1998; Watts, Illum 
1997; Yang et al., 2002; Ravikumar et al., 2009). CDDS 
would be advantageous when a delay in absorption is 
desirable from a therapeutically point of view, as for the 
treatment of diseases that have peak symptoms in the 
early morning and that exhibit circadian rhythms, such as 
nocturnal asthma, angina and rheumatoid arthritis (Halsas 
et al., 1999b, 2001a).
Natural polysaccharides such as xanthan gum, xylan 
and guar gum are not digested in the human stomach or 
small intestine, but are degraded in the colon by resident 
bacteria (Salyers et al., 1977). A suspension of natural 
polygalactomannans in polymethacrylate solution applied 
as a degradable coating around the drug core delayed 
the drug release in the small intestine, but was degraded 
by colonic bacterial enzymes thereby releasing the drug 
(Lehmann, Dreher, 1991). Xanthan gum is a high mole-
cular weight extracellular polysaccharide. The molecule 
consists of a backbone identical to that of cellulose, with 
side chains attached to alternate glucose residues. It is a 
hydrophilic polymer, which until recently had been limited 
for use in thickening, suspending and emulsifying water 
based systems (Dhopeshwarkar et al., 1994; Yeole et al., 
2006). It appears to be gaining appreciation for fabrication 
of matrices, as it not only retards drug release, but also 
provides time- independent release kinetics with added 
advantages of biocompatibility and inertness. Release of 
soluble drugs was mainly through diffusion, whereas spa-
ringly soluble or insoluble drugs were released via erosion. 
Xanthan gum has been evaluated as a hydrophilic matrix 
for controlled release preparations, using different model 
drugs including theophylline (Parfitt, 1999; Raja Sekharan 
et al., 2009), cephalexin (Kay, Alldred, 2003).
Non-steroidal anti-inflammatory drugs (NSAIDs) 
are considered to be the first-line drugs in the symptomatic 
treatment of rheumatoid arthritis (Moskowitz, 2001), os-
teoarthritis (Nisha et al., 2000) and ankylosing spondilytis 
(Medical online). Sustained release dosage forms deliver 
the drug at a slow rate over an extended period of time 
and achieve this object. Aceclofenac, (2-[2-[2-(2,6-di-
chlorophenyl) amino phenyl] acetyl] oxy acetic acid, a 
non steroidal anti-inflammatory drug (NSAID) is one of 
the emerging NSAID molecules for arthritis treatment 
(Rheumatoid arthritis guide; Drug details). Short biolo-
gical half life (about 4 hour) and dosing frequency more 
than one per day make Aceclofenac an ideal candidate for 
sustained release. It is a newer derivative of diclofenac 
and has less gastrointestinal complications. The succes-
sful treatment of arthritis depends on the maintenance of 
effective drug concentration level in the body for which 
a constant and uniform supply of drug is desired (Munira 
Momin, Pundarikakshudu, 2004; Liu, et al., 2003). In this 
study, multilayer coated system that is resistant to gastric 
and small intestinal conditions but can be easily degraded 
by colonic bacterial enzymes was designed to achieve 
effective colon delivery of aceclofenac.
MATERIALS AND METHODS
Materials
Materials used included Aceclofenac, which was 
kindly provided as a gift sample by Restek Pharma, Pondi-
cherry. Xanthan gum was purchased from Indian Research 
Products, Chennai. Eudragit S 100 and Eudragit L 100 
were purchased from Loba chemicals, Mumbai. All other 
chemicals were of analytical grade.
Preparation of Xanthan gum tablets
Step-I
Aceclofenac tablets, each containing 100 mg of 
aceclofenac and weighing 232 to 262 mg were prepared by 
wet granulation and direct compression techniques using 
xanthan gum as a polymer. Formulations (F1–F4) were 
blended and granulated with starch mucilage. The wet 
mass was passed through a mesh (1000 μm) sieve and the 
granules were dried at 50 °C for 2–3 h. The dried granules 
were sieved (650 μm), lubricated with magnesium stearate 
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and talc mixture and compressed on a single-punch tablet 
machine, using 12 mm round slightly concave punches 
(Gang Cheng et al., 2004; Lachman et al., 2004). The 
preparation of xanthan gum tablets were given in Table I.
Step -II
The optimized batches of xanthan gum tablets were 
given a coating of Eudragit L-100 and S-100 mixture in 
a fluidized bed coating apparatus. In-process samples at 
various coating levels 5, 10% w/w (% polymeric weight 
gain) were taken to check the morphology of coating to do 
dissolution studies in simulated fluids of stomach and small 
intestine. After the coating, the tablets were gently fluidized 
for about 5 min after which they were air dried in an oven 
for 24 h at 40 °C. A 10% w/w increase in the coating level 
was selected as an optimum coating percentage level for all 
the tablets. Then the pH dependent polymeric coated tablets 
were tested for drug release studies in the simulated gastric 
fluid (SGF), simulated intestinal fluid (SIF) and simulated 
colonic fluid (SCF) separately (Train 1958).
Preformulation studies
Differential scanning calorimetry
The DSC curves of Aceclofenac, xanthan gum 
and mixture of Aceclofenac/xanthan gum (10:4) were 
generated by a differential scanning calorimeter (DSC 
220C, SEIKO, Japan) at heating rate of 10 °C/min from 
60 to 200 °C. Accurately 12 mg of sample was taken in 
a standard pan and placed at sample stage. Nitrogen flow 
was set at 50 cm3/min and the nitrogen flow rate to the 
chamber was 80 cm3/min.
Fourier transforms Infrared spectroscopy
FT-IR spectra of Aceclofenac, xanthan gum and 
mixture of Aceclofenac/xanthan gum were recorded at 
room temperature in KBr pellets by applying 6000 kg/cm2 
pressure by using a Shimadzu FT-IR 8300 Spectrophoto-
meter (Shimadzu,Tokyo,Japan) in the wavelength region 
between 400 to 4000cm-1.
Standard plot of aceclofenac in pH 7.0 phosphate 
buffer saline 
100 mg of aceclofenac (standard drug) was accura-
tely weighed and dissolved using pH 7.0 phosphate buffer 
saline (PBS) solution in 100 ml standard flask and 5, 10, 
15, 20 and 25 µg/mL were prepared by suitably diluting 
the stock solutions with pH 7.0 PBS, each sample was then 
analysed spectrophotometrically at 275 nm using ELICO 
SL -159 double beam UV Visible spectrophotometer.
Evaluation of granules
The granules were evaluated for their flow proper-
ties, the Carr index (compressibility index) and Hausner 
ratio. The flow rate (g/s) was calculated from the time ne-
eded for the entire sample (40 g) to empty from the funnel. 
Bulk density was calculated from the amount of granules 
poured into a 100 mL graduated cylinder up to a total 
volume of 50 mL while for the tap density determination; 
the cylinder was tapped until no measurable change in the 
volume was observed. The bulk density (BD) and tapped 
density (TD) were calculated from equation 1 and 2.
Bulk density = Weight of the powder/Bulk volume Eq. 1
Tapped density = Weight of thr powder/Tapped volume Eq. 2
Based on bulk density and tap density, both the Carr 
Index (%) and Hausner’s ratio were calculated.
The Carr’s index was calculated by the equation 3:
Carr’s index (%) = [(TD-BD)*100] / TD Eq. 3
The Hausner’s ratio was calculated by the equation 4:
TABLE I - Composition of aceclofenac tablet
Ingredients (mg)
Quantity (mg) present in each tablet
AXT1 AXT2 AXT3 AXT4
Aceclofenac 100 100 100 100
Xanthan gum 10 20 30 40
Microcrystalline cellulose 90 90 90 90
Mucilage of starch 7.5 % 20 20 20 20
Magnesium stearate 3 % 7 7 7 7
Talc (2%) 5 5 5 5
Total 232 242 252 262
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Hausner’s Ratio = TD / BD  Eq. 4
Angle of repose was determined by fixed funnel 
method. Funnel with the end of the stem cut perpendicular 
to the axis of symmetry was secured with its tip at a given 
height (H) above a graph paper placed on a flat horizontal 
surface. The material was carefully poured through the 
funnel until the apex of the conical pile so formed just 
touches the tip of the funnel. The mean diameter of the 
base of powder cone was determined and the tangent of the 
angle of repose was calculated by equation 5: (Carr, 1965; 
Hausner, 1967; US Pharmacopeia, 2004; Bi et al., 1996).
tanα = H/R  Eq. 5
where α is the angle of repose.
Evaluation of tablets
Prepared matrix tablets were evaluated for thick-
ness by using digital micrometer (Mityato, Japan). Hard-
ness of the tablet was determined by using a Monsanto 
hardness tester, which is expressed in kg/cm2. Friability 
of the tablet was determined using Roche Friabilator, 
which is expressed in percentage. Twenty tablets were 
initially weighed (W initial) and transferred into the 
friabilator. The friabilator was operated at 25 rpm per 
min for four minutes (per 100 revolutions). The tablets 
were weighed again (Wfinal) and the percentage of friabi-
lity was then calculated by using the following formula, 
(F= Winitial-Wfinal / Winitial×100). For Weight Variation, USP 
2004 procedure for uniformity of weight was followed, 
twenty tablets were taken and their weight was determined 
individually and collectively on a digital weighing balance 
(Shimadzu, Japan). The average weight of one tablet was 
determined from the collective weight (Gohel et al., 2005; 
Chourasia, Jain, 2003; James Swarbrick, 2003).
Drug content
The drug content was determined by Absorbance 
of aliquots solutions and was measured in a spectropho-
tometer at 275 nm. Simultaneously, a 10 μg/mL of ace-
clofenac standard solution prepared in the same medium 
was recorded and content of Aceclofenac was calculated 
(United States Pharmacopoeial Convention 1999; Sinha 
et al., 2004).
In vitro drug release studies in simulated fluids
The ability of xanthan gum tablets of Aceclofenac to 
remain intact in the physiological environment of stomach 
and small intestine was assessed by mimicking mouth to 
colon transit. Drug release studies were carried out using 
USP XXIII dissolution apparatus (100 rpm, 37± 0.5 °C) 
in 900 mL of simulated gastric fluid (SGF) pH 1.2 (USP 
2008) for 2 h as the average gastric emptying time is ~2 h. 
The dissolution medium was replaced with 900 mL of 
simulated intestinal medium (SIF) pH 7.4 (USP 2008) 
and the dissolution was continued for 24 h. 1 mL of the 
sample was taken at the end of the specified time period 
and analyzed for Aceclofenac spectrophotometrically at 
275 nm. A 10 mL volume of filtered, fresh dissolution 
medium was added to make the volume after each sample 
withdrawal (Paharia et al., 2007). The susceptibility of the 
matrix tablets to the enzymatic action of colonic bacteria 
was assessed by continuing the drug release studies in 
simulated colonic fluids prepared using rat cecal content 
as described by Sinha et al. (2004).
In vitro drug release study in the presence of rat 
cecal content
Rat cecal content was prepared by taking four albino 
rats of uniform body weight (150-200 g) with no prior 
drug treatment. They were weighed, maintained on normal 
diet, and administered 1 mL of 2% dispersion of xanthan 
gum in water, and this treatment was continued for 7 days 
for polymer induction to animals. Thirty minutes before 
starting the study, each rat was humanely killed and the 
abdomen was opened. The cecal were traced, legated at 
both ends, dissected, and immediately transferred into 
phosphate buffered saline (PBS) pH 6.8, which was pre-
viously bubbled with CO2. The cecal bag was opened; the 
contents were weighed, homogenized and then suspended 
in PBS (pH 7.4) to give the desired concentration (2%) of 
cecal content, which was used as simulated colonic fluid. 
The suspension was filtered through cotton wool and ul-
trasonicated for 10 minutes in an ice bath at 40% voltage 
frequency using a probe sonicator (Soniweld, Imeco Ul-
trasonics, Mumbai, India) at 4 °C to disrupt the bacterial 
cells. After sonication, the mixture was centrifuged (Remi) 
at 2000 rpm for 20 minutes.
Tablets were placed in 200 mL of dissolution media 
(PBS, pH 7.4) containing 2% w/v rat cecal content. The 
experiment was performed with continuous CO2 supply 
into the dissolution medium. At different time intervals, 
the samples were withdrawn and replaced with fresh 
PBS. The experiment was continued up to 24 hours. The 
withdrawn samples were pipetted into a series of 10 mL 
volumetric flasks, and volumes were made up to the mark 
with PBS and centrifuged. The supernatant was filtered 
through 0.45-µm membrane filter and the filtrate analyzed 
for Aceclofenac content at 275 nm using UV spectropho-
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tometer method. All the experiments were performed 
in triplicate (Avachat et al., 2007). The interference of 
rat caecal content on the aceclofenac determination was 
not significant (P-value>0.001) and hence not taken into 
consideration.
Quantification of the water uptake and erosion 
determination
For conducting water uptake studies, the dissolution 
jars were marked with the time points of 0.5, 1, 2, up to 
9 hours. One tablet was placed in each dissolution jar 
containing 900 mL of phosphate buffer pH 7.4 buffers 
at 37 °C ± 0.5 °C, and the apparatus was run at 100 rpm 
using paddle. The tablets were taken out after completion 
of the respective stipulated time span as mentioned abo-
ve and weighed, after the excess of water at the surface 
had been removed with filter paper. The wetted samples 
were then dried in an oven at 40 °C up to constant wei-
ght. The increase of the weight on the tablet reflects the 
weight of the liquid uptake. It was estimated according to 
 Equation 6.
Q = 100 ( Ww − Wi) / Ww  Eq. 6
Where Q is the percentage of the liquid uptake, and 
Ww and Wi are the masses of the hydrated samples before 
drying and the initial starting dry weight, respectively.
The degree of erosion (expressed as percentage 
erosion of the polymer content, E) was determined using 
Equation 7.
E = 100 ( Wi − Wf ) Wi  Eq. 7
Where Wf is the final mass of the same dried and 
partially eroded sample.
The entire process was repeated to get 3 values for 
each time point, and the average was calculated.
In vitro release kinetics
In order to investigate the mode of release from 
tablets, the release data of F1 was analyzed with the 
following mathematical models: Q = Kot (Zero order 
kinetic), ln (100-Q) = lnQo-K 1 t (First order kinetic) and 
Q = Kptn (Korsemeyer and Peppas equation), where, Q is 
the percent of drug released at time t and Ko and K 1 are the 
coefficients of the equations. Kp is constant incorporating 
structural and geometric characteristics of the release devi-
ce, and n is the release exponent indicative of mechanism 
of release (Hadi, Seyed 2005).
Statistical analysis
The cumulative percent release of aceclofenac from 
tablets in different medium was compared and the statisti-
cal significance was tested using student’s t-test. A P-value 
<0.05 was considered statistically significant.
RESULTS AND DISCUSSION
DSC studies
DSC provides useful information about the physi-
cal properties of the sample as crystalline or amorphous 
nature and demonstrates a possible interaction between 
drug and polymers in formulations. The thermal curves of 
pure Aceclofenac, xanthan gum and Aceclofenac/xanthan 
gum mixture were reported in Figure 1. The thermal curve 
of Aceclofenac exhibited a profile typical of a pure, crys-
talline, anhydrous drug, with a sharp endothermic peak 
(T peak =158.3 ºC) due to its melting process. The thermal 
profile of xanthan gum revealed a melting phenonmenon 
at around 90-120 ºC, that is endothermic peak observed 
for xanthan gum at 108.9 ºC. While the drug melting peak 
is still well visible in physical mixture (Aceclofenac/xan-
than gum) thermogram at 160 ºC, Thus the thermograms 
of physical mixture showed that no interactions between 
Aceclofenac and xanthan gum. With regard to crystalli-
nity, there was no noticeable reduction in heat of fusion 
(ΔH), in physical mixtures (138.418 J/g) as compared to 
pure Aceclofenac (144.316 J/g). These suggest that the 
physical mixture could able to maintain the crystalline 
form of Aceclofenac. However it has been known that 
FIGURE 1 - DSC graphs of (a) Aceclofenac, (b) Xanthan gum, 
(c) Physical mixture of aceclofenac and xanthan gum.
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transforming the physical state of the drug to amorphous 
or partially amorphous state leads to a high energy state 
and high disorder, resulting in enhanced solubility and 
faster dissolution.
IR STUDIES
FT-IR spectral data were used to ensure no chemical 
interaction and to confirm the chemical stability of Ace-
clofenac in the physical mixture. The FTIR of Aceclofe-
nac showed intense band at 1771.47 cm-1, 1716.89 cm-1 , 
1589.53 cm-1 and 1055.9 cm-1 corresponding to the functio-
nal groups C=O, COOH, NH and OH bending. The peaks 
observed in FTIR of physical mixture of aceclofenac and 
xanthan gum was almost unchanged and was found to be 
at 1771.56 cm-1, 1716.94 cm-1, 1586.5 cm-1, 1054.5 cm-1 
respectively. Hence, all the peaks observed in plain ace-
clofenac were also observed in the physical mixture too, 
indicating no interaction of aceclofenac with the polymer. 
The IR graphs were given in Figure 2.
Micromeritic properties
The micromeritic properties of all the formulations 
were compared and presented in Table II.
The Hausner ratio is used widely in pharmaceutical 
industry as an indication of the flowability of a powder. A 
Hausner ratio less than 1.25 is considered to be an indication 
of good flowability and anything below 1.20 is regarded as 
excellent flow. The Hausner’s ratio varied from 1.19 to 1.25 
for AXT 1 to AXT4 indicating its excellent flowability. The 
Carr’s index is also used in pharmaceutics as an indication 
of the flowability of a powder and the values ranging from 
15-25 is regarded as the good value for flowability perhaps 
our observation of the result was good for all the formula-
tions. Similarly angle of repose of all the formulations were 
also good, showing good flowability.
However from all the observations, we learned 
that, AXT1 batch was optimal due to good Hausner’s 
ratio(1.19), good carr’s index(16.66) and good angle of 
repose (16°16’), which indicates the batch AXT1 granules 
have good flow property and easily compressed into ta-
blets. The results of micromeritic properties of AXT were 
given in Table II.
Physical properties
The hardness of tablet increased with the increase 
TABLE II - Physical and micromeritic properties of aceclofenac and xanthan gum granules
Test AXT1 AXT2 AXT3 AXT4
Bulk density 0.507±0.92 0.557±1.12 0.612±0.18 0.672±0.15
Tapped density 0.603±1.23 0.668±0.08 0.746±1.94 0.833±1.17
Carr’s index 18.93±1.18 19.92±0.54 21.89±1.08 23.95±1.76
Hausner’s ratio 1.19±1.67 1.22±0.65 1.23±0.87 1.25±0.67
Angle of repose 16°16’±0.35 16°78’±0.56 17°78’±1.42 19°21’±1.42
Weight (mg) 232 ± 1.02 242 ± 1.05 252 ± 0.12 263 ± 0.26
Drug content (%) 99.20± 0.20 101.2± 0.86 99.53 ± 0.12 99.16 ± 0.26
Hardness kg/cm2 5.3 ± 1.0 5.5 ± 0.15 5.6 ± 0.80 6.2 ± 1.12
Thickness (mm) 3.01 ± 0.66 3.2 ± 1.04 3.5± 1.08 3.9 ± 0.12
Friability (%) 0.17 ± 0.84 0.20 ± 0.62 0.34 ± 0.56 0.32 ± 0.48
n=3, the values are mean ± S.D
FIGURE 2 - FT-IR graphs of (a) Aceclofenac, (b) Xanthan gum, 
(c) Physical mixture of aceclofenac and xanthan gum.
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in the polymer concentrations as evident from the follo-
wing data i.e. the hardness was 5.3 kg/cm2 (AXT1) and 
it increased to 6.2 kg/cm2 (AXT4) for the rise in polymer 
concentration. Similarly the thickness also increased with 
the raised polymer concentrations. It varied from 3.01 mm 
to 4.0 mm for AXT1-AXT4 batches. The total drug content 
also varies between 99-101% for all the formulations and 
was lying within the pharmacopoeial limits. The results of 
physical properties of AXT were given in Table II.
Percentage swelling and erosion
The quantity of water uptake increased from 
15.12±0.83 to 43.15±0.45% w/v for AXT1 to AXT4 tablets 
respectively. The water uptake for each batch of tablets had 
increased upto 3rd hour and then started to decrease. This 
indicates that the xanthan gum tablets require minimum 
3 hours for reaching the maximum swelling. The results 
of swelling ratio were given in Figure 3. Where as the 
percent erosion decreased with the increase in the polymer 
concentration as the percent erosion was 25.1±0.22% w/v 
FIGURE 3 - Percentage swelling of aceclofenac-xanthan gum 
tablets (AXM 1 to AXM 4).
FIGURE 4 - Percentage erosion of aceclofenac-xanthan gum 
tablets (AXM 1 to AXM 4).
for AXT1 and 16.5±0.15% w/v for AXT4 at 30 min. While 
erosion increases with the increase in the time period so 
that erosion percentage was 76.2±0.28% w/v for AXT1 
batch and 42.2±0.08% w/v for AXT4 batch at 10
th hour. 
The results of percentage erosion are given in Figure 4.
In vitro drug release studies
The matrix tablets were subjected to in vitro drug 
release study in SGF, SIF and SCF.
In simulated gastric fluid (SGF)
The percent drug release decreased with the increase 
in the xanthan gum concentration and virtually there is no 
release at the 30th min. At the 120th min the release was 
8.1±0.26% w/v for AXT1 and it decreased towards the 
final formulation as it was found to be 1.15±0.08% w/v for 
AXT4. This is due to the time lag for swelling of the tablets. 
It requires at least 30 min for swelling and then it started 
releasing the drug, in a very controlled manner. All formu-
lation showed very low drug release in pH 1.2 buffer. This 
may be due to the less solubility of Aceclofenac in pH 1.2.
In simulated intestinal medium (SIF) and in 
simulated colonic fluid (SCF)
The cumulative drug release decreased in pH 7.4 
buffer also with the increase in the polymer concentration 
as evident from the Figure 5. In SIF, AXT1 batch showed a 
release of 4.64 ± 0.06% w/v and it reduced to 3.12 ± 0.08% 
w/v for AXT2 while there is a no release for the next two 
formulations at 30 mins. The same trend persisted at 6th 
hour i.e. drug release was 43.17 ± 0.04% w/v for AXT1 
and it decreased towards AXT4 with a drug release of 
15.13 ± 0.12 %. However the release percentage for AXT1 
FIGURE 5 - Cumulative percentage drug release of fromulations 
(AXT 1 to AXT 4) in SIF.
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was up to 101.14 ± 0.89 % w/v at the end of 12th hour in 
the dissolution medium containing pH 7.4 buffer with rat 
caecal contents (4 % w/v) and it decreased towards the 
final formulation. From this it was proved that AXT3 and 
AXT4 batch were not releasing much amount of drug in 
the stomach and intestinal medium.
From the dissolution studies conducted for AXT1, 
AXT2, AXT3 & AXT4 in simulated intestinal medium it has 
been understood that AXT1 & AXT2 tablets which were 
containing gum in 1:10 and 2:10 ratio are not protecting the 
drugs release in the gastric media. Upto 38.17 ± 0.04% w/v 
and 34.12 ± 0.12 % w/v of drug have been released from 
the AXT1 and AXT2 batches at the end of the studies where 
as AXT3 & AXT4 batch significantly (p-value<0.05) rele-
ased lesser amount of drug at the end of 6th hour.
Since the batches AXT1 & AXT2 were released 
80.15±1.04% w/v & 70.19± 0.14% w/v of the drug in the 
colonic fluid at 8th and 10th hour, they were considered as 
suitable batches for colon targeting. To prevent the drug 
release from AXT1 & AXT2 batches in the stomach & intes-
tinal media, a suitable enteric coating can be given. So that 
the drug release will be completely prevented in the SGF.
The present study was aimed to develop a targeted 
drug delivery system of Aceclofenac to treat the symptoms 
of rheumatoid arthritis. By observing the above results it 
was found that, though AXT1 and AXT2 batches released 
10.28 ± 0.83% w/v and 8.16 ± 0.48% w/v of the drug in 
simulated gastric fluid and 38.17 ± 0.04 % w/v and 34.12 
± 0.12 % w/v in the simulated intestinal fluid. They release 
upto 101.14 ± 0.89 % w/v & 89.11 ± 0.17% w/v at end of 
the 12th hour in the simulated colonic medium. If they were 
given an enteric coating, the drug release in the stomach and 
intestine can be completely prevented. The AXT3 and AXT4 
batches, though they prevent drug release in the simulated 
stomach and intestinal fluid to a considerable extent, they 
are not showing good release in the simulated colonic me-
dium. So they were not considered as suitable formulations.
So the AXT1 batch, which released a maximum 
percent of drug i.e. 80.12% w/v at the 8th hour in colonic 
medium was selected to give Eudragit coating to prevent 
the drug release in acidic medium and to start release the 
drug at the ileocaecal junction at the threshold value of pH 
upon dissolution of Eudragit in 7 or above 7.0. The results 
for cumulative drug release of various formulations in SCF 
were given in Figure 6.
Step II
The optimized batch AXT1 was given a pH depen-
dent polymeric coating to get a weight of 15% w/w to the 
tablet weight. The percentage weight gain was checked 
during the coating process to find the coating level neces-
sary to retard the drug release in simulated gastric fluid for 
2 hours. The coated tablets were subjected for dissolution 
studies in SIF and SCF.
In SGF
Upto 120 min, there was no drug release obtained 
in the simulated stomach fluid which reveals that a 15% 
w/w increase in coating level is enough to prevent the drug 
release in SGF upto 120 min.
In SIF and SCF
The percentage release was 4.88 ± 0.86 in SIF at 
the end of 6th hour and 103.12 ± 0.6% in SCF at the end 
of 24th hour. These results revealed that concentration of 
4.3% w/w of xanthan gum to tablet weight was the opti-
mized one as it released 80.64 ± 0.65% w/v in SCF at the 
end of 8th hour. The results for percentage drug release 
of E-AXT1 tablets in SIF and SCF are given in Figure 7.
FIGURE 6 - Cumulative percentage drug release of fromulations 
(AXT 1 to AXT 4) in SCF.
FIGURE 7 - Cumulative % drug release of E-AXT1in SIF and 
SCF.
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In vitro release kinetics
When the data were plotted according to the first 
order equation, all the formulation showed a fair linearity, 
with R2 value between (0.566- 0.716), when the same data 
was plotted according to the zero order equation, it shown 
a good linearity with R2 value between (0.9848 - 0.9978). 
The in vitro release kinetics of AXT1 is given in Table III.
DISCUSSION
The objective of the present study was to develop a 
controlled release colon targeted drug delivery system of 
Aceclofenac to approximate the chronobiology of rheu-
matoid arthritis. A combination of pH sensitive polymer 
coating and embedment in biodegradable matrices has 
been followed for preparation of formulations. The Eu-
dragit coated matrices of polysaccharides are assumed to 
remain intact in the physiological environment of stomach 
and small intestine but once they reach the colon, they are 
acted upon by the bacterial polysaccharidase resulting in 
degradation and release of entrapped drug. Xanthan gum 
have been reported to possess ideal qualities for sustained 
release of the drug to the targeted site ( Mundargi et al., 
2007; Sinha et al., 2007).
The xanthan gum tablets were prepared by wet 
granulation method. All the formulations showed a good 
micromeritic property. The values for Carr’s index (%) and 
Hausner’s ratio, angle of repose(°) were within specified 
range indicating good flowability, which is inturn required 
for the good tableting. Plain Aceclofenac exhibited poor 
flowability as evident by the angle of repose value of 
38.42±0.52. It was further supported by high Carr’s index 
value of 29.69±0.27 and Hausner’s ratio of 1.44±0.08 
(Mutalik et al., 2008). Where as all the prepared granu-
les possessed good flow properties as indicated by low 
values of Angle of repose (16°16’±0.35–19°21’±1.42), 
Carr’s index (18.93±1.18–23.95±1.76) and Hausner’s 
ratio (1.19±1.67–1.25±0.67). Among all the preparation, 
AXT1 was found to be good due its low Hausner’s ratio, 
TABLE III - In vitro release kinetics of AXT1-AXT4 tablets
Formulation Zero order 
R2
First order 
R2
Higuchi 
R2
Korsemeyer-Peppas
R2 ‘n’
AXT1 0.9978 0.566 0.9985 0.998 0.81
AXT2 0.9888 0.716 0.9845 0.991 0.74
AXT3 0.9865 0.701 0.9802 0.982 0.70
AXT4 0.9848 0.668 0.9824 0.979 0.73
R2: Coefficient of determination
compressibility index and angle of repose values. The 
hardness of the tablets was increased with the increase in 
xanthan gum concentration. Thus various concentrations 
of polymers had influence on physical characteristics of 
the tablets.
Evaluation of polymer swelling and erosion is a 
valuable exercise to better understand the mechanisms of 
release and the relative importance of participating para-
meters. The tablets prepared with high concentrations of 
xanthan gum showed a lower rate of erosion and a faster 
rate of swelling, as compared with the tablets containing 
lower concentrations of xanthan gum. This effect may be 
attributed to an increase of water uptake in the presence 
of a larger amount of the polymer and viscoelastic mass 
formation (Talukdar et al., 1995). Perhaps the viscoelastic 
mass formation also attributed to interaction of xanthan 
gum with the starch mucilage due to intermolecular inte-
raction (Ntawukulilyayo et al., 1996) 1, 2 After 4th h, the 
linear mechanism of water uptake is altered due to the high 
erosion percentage of the formulations and probable chan-
ge in gel structure. The swelling behavior indicated a rate 
at which this formulation absorbed water from dissolution 
media and swelled. The change in weight, characteristic 
of water uptake and swelling, started from the beginning 
and continued until 120 min of experiment and after that it 
started decreasing. The erosion measured the weight loss 
from matrix tablets immersed in dissolution media as a 
function of time. Weight loss from the tablets increased 
progressively with the erosion time. Polymer swelling 
and erosion was distinguishable among four formulations.
The evaluation of release profiles is recommended as 
an valuable exercise in the development and optimization 
of drug formulations. The release rate of aceclofenac in 
first two hours in acid media was so negligible (less than 
10%) for all the formulation that the result was not shown 
in the release curve. At this pH, Aceclofenac exists in its 
acidic form which is well known to be practically insolu-
ble in the stomach (Sheu et al., 1962; Kincl et al., 2004). 
When the dissolution was changed to pH 6.8 phosphate 
buffer media, the drug release rate was slightly increased, 
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possibly because the aceclofenac was partially converted 
to aceclofenac salt which is soluble and also because of 
swelling and erosion phenonmenon. The release of drug 
in SCF is very high due to the presence of enzymes and 
a significant differences (P-value<<0.05) was observed 
between different formulations formulated with varying 
proportions of xanthan gum. The drug release from AXT1 
(101.14 ± 0.89%) was high, while it was low for AXT4 
(89.11 ± 0.17%) at the end of the 12th hour. The reason for 
this may be low concentration of polymer in AXT1 and 
high concentration in AXT4 which caused hydration of 
xanthan gum particles in neutral medium resulted in ex-
tensive swelling. Hence it may be suggested that, the well 
Separated particles comes in contact with the dissolution 
media and thereby swollen and coalesced. This resulted 
in formation of continuous viscoelastic matrix which fills 
the interstices, maintaining the integrity of the tablet and 
retarding further liquid penetration (Dhopeshwarkar et 
al., 1993). As a result of a high swelling, Xanthan gum 
matrix tablets can sustain drug release in SCF. Xanthan 
gum has a substantial ability to swell and form a hydrogel 
in neutral medium hence the initial drug release takes place 
in SIF (Yeole et al., 2006) where as the enteric polymers 
remain insoluble in the gastric pH and intestinal pH and 
thus controlling the release of drug within the desired ran-
ge (Sinha et al., 2007) It has been reported that polymer 
concentration is found to influence the release characters 
of the drug from the dosage form (Akanksha, Raj Kumar, 
2009). 3 In our study, Xanthan gums in varying propor-
tions (4, 8, 12 and 15 % w/w to tablet weight) release the 
drug in the following order. AXT1> AXT2> AXT3> AXT4 
over a period of 8 hr in SCF.
The second part of the formulation focused on the 
polymer coating of the xanthan gum tablets. The tablets 
were coated in a fluidized bed coating apparatus. Owing 
to the ability of Eudragit S-100 and Eudragit L-100, to 
dissolve above pH 7.0 and to protect the drug in the upper 
gastrointestinal tract, they are employed in the ph sensitive 
coating. Hence when the enteric coating comes in contact 
with the colonic pH, it dissolves, and there after it is ex-
pected that drug release would be controlled by xanthan 
gum. Taking into account the dissolution profiles of all the 
xanthan gum-aceclofenac tablets, the AXT1 was selected 
as optimized formulation as its dissolution profile was 
akin to the expected requirements of the study. Further the 
Eudragit coating of the optimized formulation E-AXT1 has 
reduced the drug release to a great extent in the stomach, 
however maintain the same dissolution profile in SCF.
The drug release kinetics was evaluated by fitting 
various mathematical models, viz, zero-order, first-order, 
Higuchi, or Korsemeyer-Peppas equation. The reason why 
drug release rate from the tablet is reduced in the presence 
of increasing concentration of xanthan gum, was may due 
to the formation of a gel through which the drug must 
diffuse. The drug release kinetics of all the formulations 
were presented in table.3. Interestingly, release data of all 
the tablet formulations fitted well with zero-order release 
model with a coeficient of determination (r2) greater than 
0.99. Where as matrix tablets did not show a good fit with 
first order model with a coefficient of determination (r2) 
between 0.566-0.75. From the coefficient of determination 
values (shown in Table III), it appears that the Higuchi 
model seems the best-fitting model, which suggests a 
diffusion-controlled release mechanism by pore formation. 
The release mechanism is also influenced by porosity and 
tortuosity of the matrix (Florence, Attwood, 1988). Thus 
gradually reducing the diffusion path length, which in turn 
attenuates the decrease of the release rate in the Higuchi 
model, making the pattern to resemble zero-order model. 
The drug release data were fitted to the power law or the 
Korsemeyer-Peppas equation as shown in Table III. In 
this study, xanthan gum tablets showed a good fit into the 
Korsemeyer-Peppas equation, exhibited a c coeficient of 
determination (r2) greater than 0.98 for all the formulation. 
For the case of matrix tablets, 0.45 < n corresponds to a Fi-
ckian diffusion mechanism and n = 0.89 indicates a purely 
relaxed controlled delivery which is referred to as Case II 
transport. Intermediate values 0.45< n <0.89 indicate an 
anomalous behavior (non-Fickian kinetics corresponding 
to coupled diffusion / polymer relaxation). Occasionally, 
values of n >0.89 have been observed, which has been 
regarded as Super Case II kinetics. The calculated expo-
nents (n) were in the range from 0.70 to 0.81, indicating 
an non-Fickian diffusion mechanism. Our results clearly 
advocate the non-Fickian diffusion owing to the coupling 
of diffusion process with the mechanical response of the 
polymer. The value of n is 0.5 for Fickian transport and 
> 0.5 and < 1.0 for non-Fickian transport and 1 for zero-
order (Case-II transport). When the value of n approaches 
1.0, phenomenologically one may conclude that the relea-
se is approaching zero-order. Figs. 5-6 reveal that the rate 
of release decreased with time and this may be due to an 
increase in diffusional path length for the drug which in 
turn may be due to slower erosion rate of the rubbery layer 
and faster advancement of swelling front into the glassy 
polymer. The release pattern swiftly deviated from AXT1 
to AXT4. This may also be attributed to the synergistic 
increase in gel viscosity at the tablet periphery. This will 
decrease the rate of advancement of swelling front into the 
glassy matrix resulting in a slow diffusion of the drug. As 
the swelling front advances into the glassy polymer, the 
rubbery state, polymer (gel at the tablet periphery) which 
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is devoid of the drug, undergoes attrition. When these two 
rates are equal, the diffusional path length for the drug 
remains constant and zero-order release will be seen. The 
value of r2 was also found to be higher for the Higuchi 
model. Hence the release pattern also follows the Higuchi 
model. The solvent molecule diffuses into the polymer 
creates an osmotic pressure. The initial swelling at the 
surface then creates additional surface for the additional 
penetrant and thus leads to the formation of viscoelastic 
mass which gives its glassy state. Moreover the accumu-
lation of solvent around the periphery of tablet creates a 
solvent shock which also causes the drug release. At the 
end of the release process, all the polymer materials are 
completely dissolved in case if it follows the zero order 
and Higuchi mechanisms. The drug release slows down 
with the increase in the viscosity of the gel forming poly-
mer. The exponent ‘n’ decreases with the increase
The insoluble polymeric matrix of the table core of 
the present invention is sufficiently strong to retard the rate 
of release of the active ingredient or drug from the core. In 
addition, the tablet core provides a backbone for the outer 
rate controlling membrane. The polymeric matrix core 
prevents shrinkage and rupture of the membrane coating 
on exposure to gastrointestinal fluid. It also provides a 
tortuous path for penetrating gastrointestinal fluid, thereby 
keep a drug reservoir in the membrane coated polymeric 
matrix for a longer period of time.
From the comparative analysis of different con-
centrations of the polymers on the dissolution profile of 
the drug in the colon, we learned that the xanthan gum-
Aceclofenac formulation E-AXT1 appears promising for 
colon targeting as it inhibited drug release in upper GIT 
and exhibited maximum release in SCF in a sustained 
manner. From the over all results, it can be understood 
that the drug release takes place through the formation of 
pores and channels initially, followed by swelling of the 
polymer around the drug matrix that sustain the release 
of the drug. From the dissolution profile, it was evident 
that with the increase in polymer concentration , thickness 
of the swelling around the drug matrix increases which 
further slows down the release characteristics of the drug. 
Hence drug release could be a result of the combination of 
fine dependent hydration of xanthan gum and enzymatic 
degradation by colonic bacteria.
CONCLUSION
The present study focussed on viability of tablets 
of Aceclofenac prepared with xanthan gum for controlled 
and colon specific delivery in chronotherapy of rheuma-
toid arthritis. Xanthan gum and Eudragit coated tablets 
offer a greater degree of protection from premature drug 
release in the upper GI tract than xanthan gum alone. The 
xanthan gum is still available for enzymatic degradation, 
which allows greater drug release under conditions that 
may be expected to pertain in the colon. By changing the 
variables such as the xanthan gum to aceclofenac ratio, it 
may be possible to produce a system with a release pro-
file, which is tailored to meet the particular requirements 
of any individual drug. The in vitro studies suggest that 
xanthan gum tablets of aceclofenac are promising for the 
therapy of rheumatoid arthritis. A further detailed study in 
human subjects will through more light on their efficacy 
and compliance.
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